MedTrace Logo

Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation

NCT07101471 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 296

Last updated 2025-08-07

No results posted yet for this study

Summary

The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia. The main questions are aim to answer:

1. Is Rhofanib® (Tofacitinib) safe in Alopecia?
2. Is Rhofanib® (Tofacitinib) work to treat Alopecia?

In this study, there is no comparison group. Participants received Rhofanib® (Tofacitinib) with or without adjuvant prednisolone.

Conditions

  • Alopecia Totalis/Universalis
  • Alopecia Areata(AA)

Interventions

DRUG

Tofacitinib

Tofacitinib with a suggested dose of 5 mg twice daily with or without adjuvant prednisolone.

Sponsors & Collaborators

  • NanoAlvand

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2025-06-11
Completion
2025-06-11

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07101471 on ClinicalTrials.gov